73 results
8-K
EX-99.1
ONCR
Oncorus, Inc.
22 May 23
Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates
4:13pm
to successfully demonstrate the safety, tolerability and efficacy of its product candidates and obtain regulatory approval thereof; the adequacy of Oncorus
8-K
EX-99.1
ONCR
Oncorus, Inc.
30 Nov 22
Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer
7:07am
in this press release, including, without limitation, risks associated with: Oncorus’ ability to successfully demonstrate the safety, tolerability
8-K
ONCR
Oncorus, Inc.
30 Nov 22
Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer
7:07am
to successfully demonstrate the safety, tolerability and efficacy of ONCR-021, or any future product candidates, and obtain regulatory approval thereof
8-K
EX-99.1
ckkmbtbhq5x949
2 Nov 22
Oncorus Reports Third Quarter 2022 Financial Results and Provides Business Updates
7:11am
8-K
EX-99.1
z4t8ysbu19ag gfmywr
4 Aug 22
Oncorus Reports Second Quarter 2022 Financial Results and Provides Business Updates
9:04am
8-K
EX-99.1
gafrqujb3nlx6qg 30
23 Jun 22
Oncorus Appoints Douglas Fambrough to Board of Directors
7:21am
8-K
EX-99.1
bk9g7
4 May 22
Oncorus Reports First Quarter 2022 Financial Results and Provides Business Updates
7:15am
8-K
EX-99.1
82z09bu
5 Apr 22
Entry into a Material Definitive Agreement
7:10am
8-K
EX-99.1
r9j1 6t740o
9 Mar 22
Oncorus Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
7:46am
8-K
EX-99.1
wuw5 dghp326jla
10 Jan 22
Regulation FD Disclosure
8:17am
8-K
EX-10.1
bqw13
19 Nov 21
Entry into a Material Definitive Agreement
4:47pm